§505 (BLA)?
Executive Summary
Center for Drug Evaluation & Research is considering whether to seek legislative action to change the approval process for biologics. The current BLA process "can't change until there's a legislative action, and whether we're going to seek that is really a question," CDER Deputy Director Steven Galson, MD, said at a Lehman Brothers healthcare conference in Miami March 5. "It's going to be more of a challenge for us to have both of the sets for procedures for BLAs and NDAs in our system," Galson said. "We've got working groups focusing on that problem, whether it makes sense to change it." Galson also echoed Commissioner McClellan's comments on generic biologics, saying, "the future holds generic biologics....When that future is, is really unclear"...
You may also be interested in...
Generic Biologic Science Must Evolve Before Legislative Debate – Lumpkin
FDA and industry need to work out the science of generic biologics before a legislative debate would be useful, FDA Principle Associate Commissioner Murray Lumpkin, MD, suggested
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.